triazolam has been researched along with buspirone in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Franklin, SR; Tang, AH | 1 |
| Bliwise, NG; Cohen, SA; Dement, WC; Seidel, WF | 1 |
| Gouthro, TA; Greenblatt, DJ; Harmatz, JS; Locke, J; Shader, RI | 1 |
| Badger, G; Bickel, WK; Higgins, ST; Hughes, JR; Oliveto, AH | 1 |
| Delatte, MS; Moerschbaecher, JM; Stevenson, MW; Winsauer, PJ | 1 |
| Bates, V; Glue, P; McNaughton, N; Neo, P; Swart, C | 1 |
| Srinivas, NR | 1 |
| Glue, P; McIntosh, J; McNaughton, N; Shadli, SM | 1 |
| Glue, P; McNaughton, N; Shadli, SM; Smith, MJ | 1 |
| Byers, B; Gibbs, P; Glue, P; High, O; McNaughton, N; Shadli, SM; Steller, R | 1 |
| Atallah, ÁN; Drager, LF; Lorenzi-Filho, G; Pachito, DV; Pinto, ACPN; Rocha, A | 1 |
2 review(s) available for triazolam and buspirone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological treatment for central sleep apnoea in adults.
Topics: Acetazolamide; Adult; Aged; Apnea; Buspirone; Carbonic Anhydrase Inhibitors; Disorders of Excessive Somnolence; Female; Heart Failure; Humans; Hypnotics and Sedatives; Male; Sleep Apnea, Central; Theophylline; Triazolam | 2023 |
5 trial(s) available for triazolam and buspirone
| Article | Year |
|---|---|
Buspirone: an anxiolytic without sedative effect.
Topics: Adult; Anti-Anxiety Agents; Buspirone; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Flurazepam; Humans; Middle Aged; Pyrimidines; Sleep Initiation and Maintenance Disorders; Triazolam | 1985 |
Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies.
Topics: Administration, Oral; Adult; Affect; Analysis of Variance; Brain; Buspirone; Double-Blind Method; Electroencephalography; Female; Humans; Linear Models; Male; Memory; Psychomotor Performance; Reference Values; Time Factors; Triazolam | 1994 |
Functional antagonism of the caffeine-discriminative stimulus by triazolam in humans.
Topics: Adult; Anti-Anxiety Agents; Buspirone; Caffeine; Central Nervous System Stimulants; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Drug Interactions; Generalization, Stimulus; Humans; Hypnotics and Sedatives; Male; Psychomotor Performance; Triazolam | 1997 |
Anti-anxiety drugs reduce conflict-specific "theta"--a possible human anxiety-specific biomarker.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety; Biomarkers; Brain; Buspirone; Conflict, Psychological; Double-Blind Method; Electroencephalography; Female; Humans; Male; Triazolam; Young Adult | 2013 |
Human anxiety-specific "theta" occurs with selective stopping and localizes to right inferior frontal gyrus.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Biomarkers; Buspirone; Electroencephalography; Female; Humans; Inhibition, Psychological; Male; Neuroticism; Prefrontal Cortex; Pregabalin; Reaction Time; Theta Rhythm; Triazolam; Young Adult | 2020 |
8 other study(ies) available for triazolam and buspirone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
The discriminative stimulus effects of diazepam in rats at two training doses.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Buspirone; Carbolines; Diazepam; Discrimination Learning; Dose-Response Relationship, Drug; Flumazenil; Male; Morphine; Pentobarbital; Pyrazoles; Pyridazines; Rats; Rats, Inbred Strains; Triazolam | 1991 |
Effects of triazolam, 8-OH-DPAT, and buspirone on repeated acquisition in squirrel monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Buspirone; Conditioning, Operant; Dose-Response Relationship, Drug; Female; Reinforcement Schedule; Saimiri; Serotonin Agents; Triazolam | 2002 |
Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence.
Topics: Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Beverages; Buspirone; Caco-2 Cells; Calcium Channel Blockers; Carbamazepine; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Flurbiprofen; Food-Drug Interactions; Humans; Hypnotics and Sedatives; Hypoglycemic Agents; Lythraceae; Midazolam; Nitrendipine; Tolbutamide; Triazolam | 2013 |
An improved human anxiety process biomarker: characterization of frequency band, personality and pharmacology.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Biomarkers; Brain; Buspirone; Electroencephalography; Female; Humans; Male; Personality; Pregabalin; Psychomotor Performance; Reaction Time; Triazolam; Young Adult | 2015 |
Testing an anxiety process biomarker: Generalisation from an auditory to a visual stimulus.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety; Auditory Perception; Biomarkers; Brain Waves; Buspirone; Cerebral Cortex; Conflict, Psychological; Female; Humans; Inhibition, Psychological; Male; Triazolam; Visual Perception; Young Adult | 2016 |